Physician profile
David Pena
NPI 1972807345
$17,980.26
in general payments reported to CMS, 2019-2025
52 companies · $4,894 in 2025
The $4,894 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $2,525 · 2023: $4,681 · 2024: $5,219 · 2025: $4,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,794.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,041.22 | 2021-2025 | |
| Lilly USA, LLC | $1,741.67 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,647.08 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,602.45 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,133.97 | 2022-2025 | Repatha, Evenity, Repatha |
| Glaxosmithkline, LLC. | $971.23 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Corcept Therapeutics | $865.99 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.35 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $535.21 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $496.80 | 2023-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $427.08 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $417.98 | 2022-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $397.87 | 2025 | Recorlev |
| Esperion Therapeutics, INC. | $385.64 | 2022-2024 | Nexletol, Nexlizet |
| Vanda Pharmaceuticals INC. | $381.48 | 2024-2025 | Fanapt |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.